Spotlight on calcipotriol/betamethasone fixed-dose combination in topical formulations: is there still room for innovation?

HIGHLIGHTS

  • who: Francesca Selmin and collaborators from the Department of Pharmaceutical Sciences, Universitu00e0 degli Studi di Milano, Via Giuseppe Colombo, , Milan, Italy have published the Article: Spotlight on Calcipotriol/Betamethasone Fixed-Dose Combination in Topical Formulations: Is There Still Room for Innovation?, in the Journal: Pharmaceutics 2022, 2085 of /2022/

SUMMARY

    The combination of BD and Cal improves the clinical outcomes for the patients because it 2 of 11 has a synergistic effect: Cal mitigates atrophy and decreased epidermal barrier integrity caused by BD and BD counteracts the irritant effects of Cal. Fixed-dose . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?